# Acrivon Therapeutics, Inc.: financial statements, quarterly

ACRV · Nasdaq · CIK 1781174 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/acrv.md) · [Financials](/companies/acrv/financials.md) · [Filings](/companies/acrv/filings.md) · [Insiders](/companies/acrv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/acrv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [10.3](/filings/0000950170-24-125929.md) | [15.5 d](/filings/0000950170-25-046056.md) | [11.5](/filings/0000950170-25-071427.md) | [15.0](/filings/0000950170-25-108054.md) | [18.9](/filings/0001193125-25-280215.md) | [18.6 d](/filings/0001193125-26-115123.md) | [15.4](/filings/0001193125-26-221634.md) | [16.2](/filings/0001193125-26-346819.md) | [13.6](/filings/0001193125-25-280215.md) | [14.7 d](/filings/0001193125-26-115123.md) | [15.2](/filings/0001193125-26-221634.md) | [13.8](/filings/0001193125-26-346819.md) |
| Operating income | $m | [(16.1)](/filings/0000950170-24-125929.md) | [(21.1) d](/filings/0000950170-25-046056.md) | [(17.7)](/filings/0000950170-25-071427.md) | [(21.4)](/filings/0000950170-25-108054.md) | [(25.1)](/filings/0001193125-25-280215.md) | [(25.0) d](/filings/0001193125-26-115123.md) | [(21.7)](/filings/0001193125-26-221634.md) | [(22.6)](/filings/0001193125-26-346819.md) | [(19.7)](/filings/0001193125-25-280215.md) | [(20.1) d](/filings/0001193125-26-115123.md) | [(19.9)](/filings/0001193125-26-221634.md) | [(18.7)](/filings/0001193125-26-346819.md) |
| Net income | $m | [(14.5)](/filings/0000950170-24-125929.md) | [(19.3) d](/filings/0000950170-25-046056.md) | [(16.5)](/filings/0001193125-25-280215.md) | [(18.8)](/filings/0001193125-25-280215.md) | [(22.4)](/filings/0001193125-25-280215.md) | [(22.8) d](/filings/0001193125-26-115123.md) | [(19.7)](/filings/0001193125-26-346819.md) | [(21.0)](/filings/0001193125-26-346819.md) | [(18.2)](/filings/0001193125-25-280215.md) | [(19.0) d](/filings/0001193125-26-115123.md) | [(19.0)](/filings/0001193125-26-346819.md) | [(18.0)](/filings/0001193125-26-346819.md) |
| Diluted EPS | $ per share | [(0.66)](/filings/0000950170-24-125929.md) | not reported | [(0.73)](/filings/0000950170-25-071427.md) | [(0.52)](/filings/0000950170-25-108054.md) | [(0.59)](/filings/0001193125-25-280215.md) | not reported | [(0.51)](/filings/0001193125-26-221634.md) | [(0.55)](/filings/0001193125-26-346819.md) | [(0.47)](/filings/0001193125-25-280215.md) | not reported | [(0.49)](/filings/0001193125-26-221634.md) | [(0.43)](/filings/0001193125-26-346819.md) |
| Basic EPS | $ per share | [(0.66)](/filings/0000950170-24-125929.md) | not reported | [(0.73)](/filings/0000950170-25-071427.md) | [(0.52)](/filings/0000950170-25-108054.md) | [(0.59)](/filings/0001193125-25-280215.md) | not reported | [(0.51)](/filings/0001193125-26-221634.md) | [(0.55)](/filings/0001193125-26-346819.md) | [(0.47)](/filings/0001193125-25-280215.md) | not reported | [(0.49)](/filings/0001193125-26-221634.md) | [(0.43)](/filings/0001193125-26-346819.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [29.9](/filings/0000950170-24-125929.md) | [36.0](/filings/0000950170-25-046056.md) | [24.6](/filings/0000950170-25-071427.md) | [46.0](/filings/0000950170-25-108054.md) | [43.4](/filings/0001193125-25-280215.md) | [39.8](/filings/0001193125-26-115123.md) | [39.2](/filings/0001193125-26-221634.md) | [41.9](/filings/0001193125-26-346819.md) | [35.4](/filings/0001193125-25-280215.md) | [41.5](/filings/0001193125-26-346819.md) | [34.1](/filings/0001193125-26-221634.md) | [41.4](/filings/0001193125-26-346819.md) |
| Current assets | $m | [144](/filings/0000950170-23-061553.md) | [130](/filings/0000950170-25-046056.md) | [112](/filings/0000950170-24-059084.md) | [182](/filings/0000950170-24-095760.md) | [189](/filings/0000950170-24-125929.md) | [182](/filings/0001193125-26-115123.md) | [151](/filings/0000950170-25-071427.md) | [138](/filings/0000950170-25-108054.md) | [130](/filings/0001193125-25-280215.md) | [120](/filings/0001193125-26-346819.md) | [99.2](/filings/0001193125-26-221634.md) | [91.5](/filings/0001193125-26-346819.md) |
| Total assets | $m | [151](/filings/0000950170-23-061553.md) | [138](/filings/0000950170-25-046056.md) | [121](/filings/0000950170-24-059084.md) | [231](/filings/0000950170-24-095760.md) | [215](/filings/0000950170-24-125929.md) | [197](/filings/0001193125-26-115123.md) | [176](/filings/0000950170-25-071427.md) | [159](/filings/0000950170-25-108054.md) | [145](/filings/0001193125-25-280215.md) | [130](/filings/0001193125-26-346819.md) | [108](/filings/0001193125-26-221634.md) | [99.1](/filings/0001193125-26-346819.md) |
| Current liabilities | $m | [9.3](/filings/0000950170-23-061553.md) | [13.3](/filings/0000950170-25-046056.md) | [9.0](/filings/0000950170-24-059084.md) | [11.3](/filings/0000950170-24-095760.md) | [14.8](/filings/0000950170-24-125929.md) | [17.2](/filings/0001193125-26-115123.md) | [13.6](/filings/0000950170-25-071427.md) | [13.4](/filings/0000950170-25-108054.md) | [14.9](/filings/0001193125-25-280215.md) | [15.7](/filings/0001193125-26-346819.md) | [11.1](/filings/0001193125-26-221634.md) | [11.4](/filings/0001193125-26-346819.md) |
| Total liabilities | $m | [12.9](/filings/0000950170-23-061553.md) | [17.1](/filings/0000950170-25-046056.md) | [12.5](/filings/0000950170-24-059084.md) | [14.5](/filings/0000950170-24-095760.md) | [17.8](/filings/0000950170-24-125929.md) | [19.8](/filings/0001193125-26-115123.md) | [16.0](/filings/0000950170-25-071427.md) | [15.5](/filings/0000950170-25-108054.md) | [16.7](/filings/0001193125-25-280215.md) | [17.2](/filings/0001193125-26-346819.md) | [12.3](/filings/0001193125-26-221634.md) | [12.4](/filings/0001193125-26-346819.md) |
| Shareholders' equity | $m | [138](/filings/0000950170-24-125929.md) | [121](/filings/0001193125-26-115123.md) | [108](/filings/0001193125-25-280215.md) | [216](/filings/0001193125-25-280215.md) | [197](/filings/0001193125-25-280215.md) | [177](/filings/0001193125-26-346819.md) | [160](/filings/0001193125-26-346819.md) | [143](/filings/0001193125-26-346819.md) | [129](/filings/0001193125-25-280215.md) | [113](/filings/0001193125-26-346819.md) | [95.5](/filings/0001193125-26-346819.md) | [86.7](/filings/0001193125-26-346819.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.8) d](/filings/0000950170-24-125929.md) | [(12.4) d](/filings/0000950170-25-046056.md) | [(17.1)](/filings/0000950170-25-071427.md) | [(13.9) d](/filings/0000950170-25-108054.md) | [(17.3) d](/filings/0001193125-25-280215.md) | [(17.4) d](/filings/0001193125-26-115123.md) | [(19.5)](/filings/0001193125-26-221634.md) | [(16.6) d](/filings/0001193125-26-346819.md) | [(12.3) d](/filings/0001193125-25-280215.md) | [(15.2) d](/filings/0001193125-26-115123.md) | [(20.5)](/filings/0001193125-26-221634.md) | [(14.9) d](/filings/0001193125-26-346819.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-125929.md) | [1.2 d](/filings/0000950170-25-046056.md) | [0.8](/filings/0000950170-25-071427.md) | [0.1 d](/filings/0000950170-25-108054.md) | [1.0 d](/filings/0001193125-25-280215.md) | [0.8 d](/filings/0001193125-26-115123.md) | [0.1](/filings/0001193125-26-221634.md) | [0.5 d](/filings/0001193125-26-346819.md) | [0.9 d](/filings/0001193125-25-280215.md) | [0.2 d](/filings/0001193125-26-115123.md) | [0.0](/filings/0001193125-26-221634.md) | [0.1 d](/filings/0001193125-26-346819.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.8](/filings/0000950170-23-061553.md) | [21.9](/filings/0000950170-24-059084.md) | [22.0](/filings/0000950170-24-095760.md) | [22.1](/filings/0000950170-24-125929.md) | [22.6](/filings/0000950170-25-071427.md) | [36.1](/filings/0000950170-25-108054.md) | [38.1](/filings/0001193125-25-280215.md) | [38.4](/filings/0001193125-26-221634.md) | [38.5](/filings/0001193125-26-346819.md) | [38.6](/filings/0001193125-25-280215.md) | [38.7](/filings/0001193125-26-221634.md) | [41.8](/filings/0001193125-26-346819.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,853,362 at 2026-08-07, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-346819.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.